Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibition
Theresa Baumeister,Andrea Isabel Proano Vasco,Amira Metwaly,Karin Kleigrewe,Alexander Kuznetsov,Linus Schoemig,Martin Borgmann,Mohammed Khiat,Akanksha Anand,Katrin Boettcher,Dirk Haller,Andreas Dunkel,Veronika Somoza,Sinah Reiter,Chen Meng,Robert Thimme,Roland Schmid,Deepa Patil,Elke Burgermeister,Yiming Huang,Yiwei Sun,Harris Wang,Timothy Cragin Wang,Julian Abrams,Michael Quante
DOI: https://doi.org/10.1101/2024.06.11.598405
2024-06-12
Abstract:Background: The incidence of Barrett esophagus (BE) and Gastroesophageal Adenocarcinoma (GEAC) correlates with obesity and a diet rich in fat. Bile acids (BA) support fat digestion and undergo microbial metabolization in the gut. The farnesoid X receptor (FXR) is an important modulator of the BA homeostasis. The capacity of inhibiting cancer-related processes when activated, make FXR an appealing therapeutic target. In this work, we assess the role of diet on the microbiota-BA axis and evaluate the role of FXR in disease progression. Results: Here we show that high fat diet (HFD) accelerated tumorigenesis in L2-IL1B mice (BE- and GEAC- mouse model) while increasing BA levels and enriching gut microbiota that convert primary to secondary BA. While upregulated in BE, expression of FXR was downregulated in GEAC in mice and humans. In L2-IL1B mice, FXR knockout enhanced the dysplastic phenotype and increased Lgr5 progenitor cell numbers. Treatment of murine organoids and L2-IL1B mice with the FXR agonist obeticholic acid (OCA) deacelerated GEAC progression. Conclusion: We provide a novel concept of GEAC carcinogenesis being accelerated via the diet- microbiome-metabolome axis and FXR inhibition on progenitor cells. Further, FXR activation protected with OCA ameliorated the phenotype in vitro and in vivo, suggesting that FXR agonists have potential as differentiation therapy in GEAC prevention.
Cancer Biology